The serotonin syndrome and its treatment

被引:193
作者
Gillman, PK
机构
[1] Mount Pleasant, QLD 4740
关键词
chlorpromazine; cyproheptadine; serotonin antagonists; serotonin syndrome; treatment;
D O I
10.1177/026988119901300111
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine. The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various subtypes of serotonin receptors. There is no effective drug treatment established. The history of the treatment of serotonin syndrome with 5-hydroxytryptamine blocking drugs is reviewed. A literature search was undertaken using both Medline and a manual search of the older literature. Reports of cases treated with the 5-HT2 blockers cyproheptadine and chlorpromazine were identified and analysed. There is some evidence suggesting the efficacy of chlorpromazine and cyproheptadine in the treatment of serotonin syndrome. The evidence for cyproheptadine is less substantial, perhaps because the dose of cyproheptadine necessary to ensure blockade of brain 5-HT2 receptors is 20-30 mg, which is higher than that used in the cases reported to date (4-16 mg).
引用
收藏
页码:100 / 109
页数:10
相关论文
共 142 条
  • [1] AMES D, 1993, JAMA-J AM MED ASSOC, V269, P869, DOI 10.1001/jama.269.7.869
  • [2] REVIEW OF COMBINED TRICYCLIC AND MAOI THERAPY
    ANANTH, J
    LUCHINS, D
    [J]. COMPREHENSIVE PSYCHIATRY, 1977, 18 (03) : 221 - 230
  • [3] [Anonymous], J INT MED RES
  • [4] TURNOVER OF BRAIN MONOAMINE-OXIDASE MEASURED INVIVO BY POSITRON EMISSION TOMOGRAPHY USING L-[C-11]DEPRENYL
    ARNETT, CD
    FOWLER, JS
    MACGREGOR, RR
    SCHLYER, DJ
    WOLF, AP
    LANGSTROM, B
    HALLDIN, C
    [J]. JOURNAL OF NEUROCHEMISTRY, 1987, 49 (02) : 522 - 527
  • [5] AYD F J Jr, 1961, J Neuropsychiatr, V2(Suppl 1), P119
  • [6] AYD FJ, 1961, DIS NERV SYST, V22, P388
  • [7] BABIAK W, 1961, CAN MED ASSOC J, V85, P377
  • [8] SEROTONIN SYNDROME FROM FLUVOXAMINE AND BUSPIRONE
    BAEZ, M
    MALCOLM, D
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1995, 40 (07): : 428 - 429
  • [9] BEASLEY CM, 1993, J CLIN PSYCHOPHARM, V13, P312
  • [10] Benazzi F, 1996, PHARMACOPSYCHIATRY, V29, P162